Skip to main
PSNL

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 0%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Personalis Inc has shown a promising trajectory with a significant ~28% increase in stock value following the announcement of Medicare coverage and pricing for its proprietary NeXT Personal MRD test, particularly in breast cancer. The company has strategically managed its cash burn and margins in Q3 while positioning for accelerated growth in volumes, particularly through its partnership with Tempus, which is expected to enhance marketing efforts for Personalis's tests. Furthermore, the successful reimbursement in breast cancer is anticipated to catalyze earlier positive reimbursement decisions for immuno-oncology monitoring in other cancer indications, leading to upward adjustments in sales estimates for 2026 and beyond.

Bears say

Personalis Inc. has lowered its revenue guidance for 2025 to $68-$73 million, a decrease from previous expectations of $70-$80 million, primarily due to a slowdown in biopharma revenue linked to logistical issues and delays in reimbursement for clinical tests. The firm is facing challenges in accurately forecasting sample flow from its biopharma clients, which adds uncertainty to its revenue potential. Additionally, there are concerns regarding ongoing losses and debt on the balance sheet, indicating that maintaining profitability may be an ongoing struggle for the company.

Personalis Inc (PSNL) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 0% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Personalis Inc (PSNL) has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.